NEW DATA SHOW ENDOCUFF VISION IMPROVES OVERALL PERFORMANCE IN COLONOSCOPY AND INCREASES ADENOMA DETECTION RATE

London, Monday 18 May 2015. 07:00 AM BST. Norgine B.V.’s partner Arc Medical Design Ltd. today announced that the device ENDOCUFF™ can significantly improve overall colonoscopy performance by

• Making the colonoscopy quicker Caecal intubation time (CIT) – 22.36%,p<0.005
• Increasing Adenoma Detection Rate (ADR) – 13.8%,p<0.05
• Increasing Mean number of adenomas per procedure (MAP) – 83%,p<0.05.

This prospective observational study was presented at Digestive Disease Week 2015.[1]

ENDOCUFF™ is a simple device attached at the end of the colonoscope that opens up the field of view by retracting folds during withdrawal.

The study was divided in three consecutive periods: pre-cuff (no device used), during-cuff (device used) and post-cuff (no device used). Key quality colonoscopy indicators used were Adenoma Detection Rate, Mean number of adenomas per procedure and Caecal intubation time with a total number of procedures performed was 399.

Peter Martin, COO at Norgine said: “Improving quality of endoscopy is important because effective colon cancer screening lowers colon cancer rates and mortality. ENDOCUFF™ can transform patient’s care because it clearly improves diagnosis  of lesions but also delivers better quality colonoscopy.”

Tas Javed, MD at Arc Medical said: “ENDOCUFF™ is already available for use in the US and in Europe and we are confident that extensive use of the device when performing colonoscopy will help save lives and has the potential to ultimately reduce healthcare bills.”

Colorectal cancer is the second most common cause of cancer-related mortality in the world,[2] with 412,00 new diagnoses every year in Europe.[3]^,[4]

Other data presented at DDW included:

• ENDOCUFF™ assisted colonoscopy increased the detection of polyps: a prospective study of crossover colonoscopies using a colorectal anatomic model. Sa1607. 09:30 – 16:00. Saturday 16 May 2015. DDW 2015. 
• Improved polyp detection among high risk patients with ENDOCUFF™. Sa1613. 09:30-16:00. Saturday 16 May 2015. DDW 2015.
• Adenoma detection with ENDOCUFF™ colonoscopy vs. conventional colonoscopy: a multicenter randomised controlled trial. Presentation 434, 17 May 2015. 14:30 -14:45. DDW 2015.

ends

NOTES TO EDITORS:

About ENDOCUFF VISION^TM

ENDOCUFF VISION^™ is a single-use endoscopic overtube, which fits onto the distal end of an endoscope. The size of the device is approximately 2.5cm long by 1.5cm wide (3.5cm with arms extended), and is of minimal weight.

ENDOCUFF VISION^™ has unique hinged arms that lie flat against the shaft of the endoscope to create a smooth, low friction surface during intubation. During extubation the arms of the device flare out to stabilise the tip of the endoscope and centre it in the lumen, providing greater control and enabling the physician to flatten the folds of the colon, leading to superior visualisation.

The device is manufactured in the UK by Boddingtons Plastics Limited, a plastics manufacturer, which currently holds the CE mark for the product.

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

ENDOCUFF VISION is a registered trademark of Arc Medical Design Ltd.

About Arc Medical Design Ltd.

Providing award-winning and innovative products worldwide, Arc Medical are leading the way in increasing Adenoma Detection Rates (ADR) and improving retrieval methods.

As a clinician driven company, Arc Medical is uniquely positioned to understand the needs of those working in the gastro-intestinal sector and strives to improve physician experience and patient outcome. 

Media Contacts

Isabelle Jouin : +44 (0)1895 453643

Charlotte Andrews: +44 (0)1895 453669

Follow us @norgine

Arc Medical Design Ltd:
Tas Javed: +44 (0)113 242 0131

May 2015. GL/COR/0515/0039